AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04607980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 654
Description: Participants will receive SC injection of ABP 654.
Study NCT04607980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Participants will receive SC injection of ustekinumab.
Study NCT03965455 — intervention group
Intervention type: DEVICE
Intervention: Diode laser
Description: In the laser-assisted frenectomy, a diode laser device (GIGA Cheese II®, China) (λ= 810 nm) with a 400 µm diameter, plain-ended optical ﬁber tip was used for the procedure maintaining contact with oral mucosa at 2,5 W, 70 Hz frequency with a short pulse (140 microseconds) duration.
Study NCT03965455 — intervention group
Intervention type: PROCEDURE
Intervention: Conventional
Description: In the conventional frenectomy, the incisions were applied using a scalpel blade no.15 on the upper and lower surface of the haemostat until the frenum was excised.
Study NCT03027076 — intervention group
Intervention type: PROCEDURE
Intervention: Genitourinary Specimen Collection
Description: Collect urethral swab, urine before prostatic massage (pre-M), urine after prostatic massage (post-M) and Expressed Prostatic Secretion (EPS)
Study NCT03027076 — intervention group
Intervention type: PROCEDURE
Intervention: Collect midstream urine samples
Description: Collect midstream urine samples
Study NCT03211728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo group receive placebo 150 mg 1 hour before surgery and 12 hours after initial dose.
Study NCT01764659 — intervention group
Intervention type: OTHER
Intervention: Contrast-enhanced 4D computed tomography
Description: All enrolled patients each underwent three CT scans: a 4DCT immediately following a contrast-enhanced 3DCT and an individually optimized contrast-enhanced 4DCT.
Study NCT04564924 — intervention group
Intervention type: RADIATION
Intervention: DXA
Description: Bone mineral density was examined in all cases and controls
Study NCT00570180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 21 day-cycle Induction therapy:bortezomib 1.3 mg/m2 (I.V. Days 1, 4, 8, and 11), then 10-day rest period. DOXIL 30 mg/m2 given after bortezomib (I.V. infusion Day 4 of each cycle). Dexamethasone 40 mg PO on days 1-4,8-11 and 15-18 during the first cycle. Subsequent 3 cycles, dexamethasone 40 mg PO given on days 1-4 and 11-14. Patients who don't progress may undergo elective stem cell mobilization, stem cell collection and cryopreservation. Patients will then receive post-induction therapy 1.5 mg/m2 bortezomib days 1, 8, and 15 I.V. + cyclophosphamide 300 mg/m2 PO weekly + prednisone 100 mg PO on alternate days for 8 monthly 28 day cycles.Maintenance therapy with weekly 40 mg dexamethasone (days 1, 8, 15 and 22) every month until disease progression occurs.
Study NCT02929134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients \<50 kg)
Study NCT02929134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily tablet for 6 weeks: matching tablets containing no active ingredients
Study NCT02687295 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Thylakoids
Study NCT02687295 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study NCT02550704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy with eleven biopsies in the left colon to assess intestinal permeability
Description: Eleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin, occludin and ZO-1.
Study NCT00524173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir & Emtricitabine
Study NCT00524173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Study NCT02840396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: repetitive TMS (rTMS) can lead to temporary increases or decreases (depending on the protocol used) in excitability of the targeted area. This change in excitability has been shown to last beyond the duration of the stimulation.
Study NCT02840396 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham rTMS (or placebo rTMS) refers to a control condition in which no physiological effect on the targeted cortical region occurs.
Study NCT03864289 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent skills training
Description: Parents of children with autism spectrum disorder attend the parental training course once a week, and there was a total of eight courses with each course lasting 3 hours
Study NCT03818776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (MEDI4736) is an anti-PD-L1 monoclonal antibody immunotherapy for lung cancer. Participants will receive 1500mg durvalumab via intravenous (IV) infusion Q4W for up to a maximum of 12 months (up to 13 doses/cycles) with the last administration on week 48 unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. (N.b. If a participant's weight falls to 30kg (≤30 kg)), then the participant should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W after consultation between Investigator and Study Physician, until the weight improves to above 30 kg >30 kg, at which point the participant should start receiving the fixed dosing of durvalumab 1500 mg Q4W).
Study NCT03818776 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton beam therapy RT
Description: Proton beam therapy is a type of RT where the proton stops at a specific depth according to its energy which allows for a sufficient tumor dose that may improve local control and survival while sparing normal organs at risk, such as the heart, lung, and spinal cord.
Study NCT00473824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis C Immune Globulin Intravenous (Human) 5%
Description: Hepatitis C Immune Globulin Intravenous (Human) 5%, \[Civacir\]: 18 infusions total, per schedule, of 300 or 400 mg/kg of body weight given with standard post-transplant therapy inclusive of immunosuppressive agents.
Study NCT05822206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-TSC
Description: Cognitive Behavioral Therapy for Trauma and Self-Care
Study NCT05822206 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Life Steps and Sexual Decision-Making
Study NCT05822206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Steps and Sexual Decision-Making
Study NCT02589834 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quran group
Study NCT02696434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: daily dosing
Study NCT02696434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: daily dosing
Study NCT03381469 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comprehensive periodontal treatment
Description: The Case group participants will receive non-surgical periodontal therapy that will be completed by the end of week 20-21 of gestation. This will consist of oral hygiene instruction with comprehensive periodontal treatment which will include excavation and sealing of cavities, removal of overhanging restorations, extraction of hopeless teeth followed by supragingival and subgingival scaling and root planing (SRP) of sites with PDs > 4 mm and polishing of all the teeth. Participants will be offered treatment under local anesthetic when necessary. No limits will be imposed on the number of dental visits needed to accomplish periodontal therapy.
Study NCT03381469 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single visit supragingival scaling
Description: The control and Placebo group participants will receive oral hygiene instruction and supragingival cleaning of all teeth at their baseline visit.
Study NCT02696434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: daily dosing
Study NCT02696434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: daily dosing
Study NCT05213026 — intervention group
Intervention type: PROCEDURE
Intervention: Regenerative endodontics
Description: Regenerative endodontic procedure with 3 Mix-MP
Study NCT04126096 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Skin Testing beta-lactams
Description: Percutaneous skin prick followed by Intradermal Injections of NMBAs at increasing concentrations compared with an established positive and negative control.
Study NCT03636945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET at 18F-FDOPA
Description: 18F-fluorodihydroxyphenylalanine (18F-FDOPA) PET imaging
Study NCT02105636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT02105636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Study NCT02105636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Study NCT02105636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT01439087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGH Optical Frequency Domain Imaging (OFDI) System
Description: Imaging of Colonic Polyps with OFDI system
Study NCT03413410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Patients with acute coronary syndrome take metoprolol during hospital and after discharge in the optimal dosing pathway.
Study NCT03010579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythropoietin
Description: Erythropoietin will be administered subcutaneously (s.c.) at the dose of 10 000 IU, three times a week. If necessary,oral ferrous succinate vitamins B12 and folic acid will be administered.
Study NCT03010579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iron supplementation
Description: If necessary, oral ferrous succinate, vitamins B12 and folic acid will be administered.
Study NCT05551481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: To evaluate the clinical performance of indirect resin composite restorations, which were luted with two different resin cement, in posterior teeth for up to 2 years.
Description: resin cement (Variolink II, Ivoclar Vivadent)-self-adhesive resin cement (Relyx U200, 3M ESPE)
Study NCT05551481 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: To evaluate the clinical performance of indirect resin composite restorations, which were luted with two different resin cement, in posterior teeth for up to 2 years.
Description: resin cement (Variolink II, Ivoclar Vivadent)-self-adhesive resin cement (Relyx U200, 3M ESPE)
Study NCT02329106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible electroporation (IRE) is a new, minimal-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels,bile ducts and diaphragmatic dome.
Study NCT01391143 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGA271
Description: Up to 9 dose escalation cohorts will be enrolled to determine the maximum tolerated dose of MGA271. Patients with evidence of clinical benefit will be allowed to continue therapy at the same dose once per week for 3 weeks out of every 4-week cycle until documented progression.~Patients treated in the Expansion Segment at the maximum administered dose will receive weekly, uninterrupted infusions of MGA271 in 8 week cycles for up to 12 cycles.
Study NCT04284761 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bicalutamide implant
Description: Biolen bicalutamide implant
Study NCT00358215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Administered by subcutaneous injection
Study NCT00358215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study NCT01806935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DC086
Study NCT01806935 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00458393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daily TDF/FTC
Description: daily oral medication
Study NCT00458393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily oral medication
Study NCT03184818 — intervention group
Intervention type: OTHER
Intervention: Advanced care
Description: The pharmacist will assess for symptoms of urinary tract infection and, for patients in Arm 1, prescribe antibacterials when appropriate. For patients in Arm 2, pharmacists will ensure optimal therapy and adapt or perform therapeutic substitution when appropriate (or work with the patient to discontinue therapy or just put the prescription on file in instances where the patient is assessed to have asymptomatic bacteriuria for which treatment is inappropriate).
Study NCT03246802 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR partial prostate brachytherapy
Description: temporary radioactive implant
Study NCT01507532 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pharmacokinetic monitoring
Description: pharmacokinetic monitoring
Study NCT03303391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intradialytic Blood Pressure Slope Based Ultrafiltration
Description: Algorithmic Determination of ultrafiltration based on intradialytic blood pressure slopes calculated at the beginning of each month from the prior two weeks of dialysis treatments
Study NCT01134289 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar sympathetic block
Description: unilateral lumbar sympathetic block at L3 level using 0.2% chirocaine under C-arm fluoroscopy
Study NCT04318132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nidek Mirante
Description: The Nidek Mirante Optical Coherence Tomography (OCT) including scanning laser ophthalmoscope (SLO) function is an non-contact system for imaging the fundus and for axial cross sectional imaging of anterior and posterior ocular structures.
Study NCT04318132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optovue RTVue XR Avanti
Description: The Avanti is an optical coherence tomography system indicated for the in vivo imaging,axial cross-sectional, and three-dimensional imaging and measurement of anterior and posterior ocular structures.
Study NCT04318132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optos P200DTx
Description: The P200DTx scanning laser ophthalmoscope (SLO) is indicated for use as a widefield and retinal fluorescence and autofluorescence imaging ophthalmoscope to aid in the diagnosis and monitoring of diseases and disorders that manifest in the retina.
Study NCT03129295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPC-SHRC
Description: Oral tablet four times a day for 3 days
Study NCT03129295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Oral tablet four times a day for 3 days
Study NCT00858468 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza virus vaccine (2004-2005 Formulation)
Description: 0.25 mL, Intramuscular
Study NCT04655534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Warm-up (IMW)
Description: The IMW protocol applied before each inspiratory muscle training (IMT) session by using a threshold inspiratory muscle trainer. The IMW protocol consists of 2 sets of 30 breaths in 40% of the maximal inspiratory pressure (MIP), with 1 min rest between sets. The intensity of MIP adjusted by two weekly MIP measurements.
Study NCT04655534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Description: The IMT applied twice a day as 30 breath repetitions at 60% of the maximal inspiratory pressure (MIP). The intensity of MIP adjusted by two weekly MIP measurements.
Study NCT04655534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory exercises and aerobic exercise program
Description: Then the respiratory exercises and aerobic exercise program performed in both groups in each session. Aerobic exercise program; After 5 min of general body warming, applied 20 min with a load of 4-6 according to the modified Borg scale on the treadmill, finished with 5 min whole body cool-down. All program applied to 3 days a week for 8 weeks under the supervision of a physiotherapist and other days of the week without a supervisor.
Study NCT01202552 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: seasonal influenza vaccine
Description: receives a single intramuscular dose of 0.5 ml of trivalent influenza vaccine, containing at least 15 microgram of hemagglutinin antigen per strain
Study NCT01202552 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: seasonal influenza vaccine
Description: receives two-site intradermal dose of 0.1 ml each, containing at least 3 microgram of hemagglutinin antigen per strain per site and group
Study NCT01202552 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: seasonal influenza vaccine
Description: receives two-site intradermal dose of 0.2 ml each, containing at least 6 microgram of hemagglutinin antigen per strain per site
Study NCT01260584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: One 10 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.
Study NCT01260584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: One 75 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.
Study NCT02026869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin is taken either orally or vaginally every 12 hours
Study NCT02600585 — intervention group
Intervention type: BIOLOGICAL
Intervention: Recombinant Influenza Vaccine
Description: Intramuscular injection of study vaccine
Study NCT02600585 — intervention group
Intervention type: BIOLOGICAL
Intervention: Inactivated Influenza Vaccine
Description: Intramuscular injection of study vaccine
Study NCT04187430 — intervention group
Intervention type: BEHAVIORAL
Intervention: Retrospective
Description: Those patients with a positive sample for ICD will be randomly selected from the microbiology database.
Study NCT00445744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00445744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV
Study NCT00445744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV or PO
Study NCT00445744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study NCT00445744 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis
Description: Correlative studies
Study NCT00445744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT00445744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00445744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Correlative studies
Study NCT00445744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo PBPC transplantation
Study NCT00445744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic transplantation
Study NCT04081116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symmetric settings (high pressures/fast rate)
Description: Describes settings on the MI-E device
Study NCT04081116 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Symmetric settings (high pressures/fast rate)
Description: Describes settings on the MI-E device
Study NCT04081116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asymmetric settings (Pi<Pe/Ti>Te)
Description: Lower insufflation pressures at longer times
Study NCT04081116 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Asymmetric settings (Pi<Pe/Ti>Te)
Description: Lower insufflation pressures at longer times
Study NCT04081116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preinclusion settings
Description: Settings in use at start of study
Study NCT04081116 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Preinclusion settings
Description: Settings in use at start of study
Study NCT02236078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose isoniazid
Description: See arm description
Study NCT01037816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FS-67 Patch
Description: One FS-67 patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
Study NCT01037816 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: One placebo patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
Study NCT00926536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-arm CT + DSA as needed
Description: C-arm CT images obtained and supplemented with DSA if needed